The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How does the mutation profile differ between patients with MDS–AML and de novo AML?

During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to James Yu, AdventHealth Orlando, Orlando, US. We asked, How does the mutation profile differ between patients with MDS–AML and de novo AML?

How does the mutation profile differ between patients with MDS–AML and de novo AML?

In this video, Yu discusses a study comparing the differences in chromosomal mutations between AML with myelodysplasia-related changes (MRC) and AML with no clinical history of prior myelodysplastic syndrome. Results indicate that the non-MRC group exhibited a more dynamic genomic profile when compared to the AML-MRC group.

Share: